• Je něco špatně v tomto záznamu ?

A Multi-Biochemical and In Silico Study on Anti-Enzymatic Actions of Pyroglutamic Acid against PDE-5, ACE, and Urease Using Various Analytical Techniques: Unexplored Pharmacological Properties and Cytotoxicity Evaluation

M. Šudomová, STS. Hassan, H. Khan, M. Rasekhian, SM. Nabavi,

. 2019 ; 9 (9) : . [pub] 20190821

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025714

In the current study, pyroglutamic acid (pGlu), a natural amino acid derivative, has efficiently inhibited the catalytic activities of three important enzymes, namely: Human recombinant phosphodiesterase-5A1 (PDE5A1), human angiotensin-converting enzyme (ACE), and urease. These enzymes were reported to be associated with several important clinical conditions in humans. Radioactivity-based assay, spectrophotometric-based assay, and an Electrospray Ionization-Mass Spectrometry-based method were employed to ascertain the inhibitory actions of pGlu against PDE5A1, ACE, and urease, respectively. The results unveiled that pGlu potently suppressed the activity of PDE5A1 (half-maximal inhibitory concentration; IC50 = 5.23 µM) compared with that of standard drug sildenafil citrate (IC50 = 7.14 µM). Moreover, pGlu at a concentration of 20 µg/mL was found to efficiently inhibit human ACE with 98.2% inhibition compared with that of standard captopril (99.6%; 20 µg/mL). The urease-catalyzed reaction was also remarkably inactivated by pGlu and standard acetohydroxamic acid with IC50 values of 1.8 and 3.9 µM, respectively. Remarkably, the outcome of in vitro cytotoxicity assay did not reveal any significant cytotoxic properties of pGlu against human cervical carcinoma cells and normal human fetal lung fibroblast cells. In addition to in vitro assays, molecular docking analyses were performed to corroborate the outcomes of in vitro results with predicted structure-activity relationships. In conclusion, pGlu could be presented as a natural and multifunctional agent with promising applications in the treatment of some ailments connected with the above-mentioned anti-enzymatic properties.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025714
003      
CZ-PrNML
005      
20201222160340.0
007      
ta
008      
201125s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/biom9090392 $2 doi
035    __
$a (PubMed)31438631
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Šudomová, Miroslava $u Museum of literature in Moravia, Klášter 1, 664 61 Rajhrad, Czech Republic.
245    12
$a A Multi-Biochemical and In Silico Study on Anti-Enzymatic Actions of Pyroglutamic Acid against PDE-5, ACE, and Urease Using Various Analytical Techniques: Unexplored Pharmacological Properties and Cytotoxicity Evaluation / $c M. Šudomová, STS. Hassan, H. Khan, M. Rasekhian, SM. Nabavi,
520    9_
$a In the current study, pyroglutamic acid (pGlu), a natural amino acid derivative, has efficiently inhibited the catalytic activities of three important enzymes, namely: Human recombinant phosphodiesterase-5A1 (PDE5A1), human angiotensin-converting enzyme (ACE), and urease. These enzymes were reported to be associated with several important clinical conditions in humans. Radioactivity-based assay, spectrophotometric-based assay, and an Electrospray Ionization-Mass Spectrometry-based method were employed to ascertain the inhibitory actions of pGlu against PDE5A1, ACE, and urease, respectively. The results unveiled that pGlu potently suppressed the activity of PDE5A1 (half-maximal inhibitory concentration; IC50 = 5.23 µM) compared with that of standard drug sildenafil citrate (IC50 = 7.14 µM). Moreover, pGlu at a concentration of 20 µg/mL was found to efficiently inhibit human ACE with 98.2% inhibition compared with that of standard captopril (99.6%; 20 µg/mL). The urease-catalyzed reaction was also remarkably inactivated by pGlu and standard acetohydroxamic acid with IC50 values of 1.8 and 3.9 µM, respectively. Remarkably, the outcome of in vitro cytotoxicity assay did not reveal any significant cytotoxic properties of pGlu against human cervical carcinoma cells and normal human fetal lung fibroblast cells. In addition to in vitro assays, molecular docking analyses were performed to corroborate the outcomes of in vitro results with predicted structure-activity relationships. In conclusion, pGlu could be presented as a natural and multifunctional agent with promising applications in the treatment of some ailments connected with the above-mentioned anti-enzymatic properties.
650    _2
$a vazebná místa $7 D001665
650    _2
$a kaptopril $x chemie $x metabolismus $7 D002216
650    _2
$a buněčné linie $7 D002460
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a cyklické nukleotidfosfodiesterasy, typ 5 $x chemie $x genetika $x metabolismus $7 D054706
650    _2
$a lidé $7 D006801
650    _2
$a kyseliny hydroxamové $x antagonisté a inhibitory $x metabolismus $7 D006877
650    _2
$a inhibiční koncentrace 50 $7 D020128
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a angiotensin konvertující enzym $x chemie $x genetika $x metabolismus $7 D007703
650    _2
$a terciární struktura proteinů $7 D017434
650    _2
$a kyselina pyrrolidonkarboxylová $x chemie $x metabolismus $x toxicita $7 D011761
650    _2
$a rekombinantní proteiny $x biosyntéza $x chemie $x izolace a purifikace $7 D011994
650    _2
$a sildenafil citrát $x chemie $x metabolismus $7 D000068677
650    _2
$a hmotnostní spektrometrie s elektrosprejovou ionizací $7 D021241
650    _2
$a spektrofotometrie $7 D013053
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a ureasa $x antagonisté a inhibitory $x metabolismus $7 D014510
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hassan, Sherif T S $u Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Palackého tř. 1946/1, 612 42 Brno, Czech Republic. sherif.hassan@seznam.cz.
700    1_
$a Khan, Haroon $u Department of Pharmacy, Abdul Wali Khan University, Mardan 23200, Pakistan.
700    1_
$a Rasekhian, Mahsa $u Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah 6734667149, Iran.
700    1_
$a Nabavi, Seyed Mohammad $u Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran 14359-16471, Iran. nabavi208@gmail.com.
773    0_
$w MED00188737 $t Biomolecules $x 2218-273X $g Roč. 9, č. 9 (2019)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31438631 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222160336 $b ABA008
999    __
$a ok $b bmc $g 1599859 $s 1116400
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 9 $c 9 $e 20190821 $i 2218-273X $m Biomolecules $n Biomolecules $x MED00188737
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace